Flexion Therapeutics, Inc. (FLXN) stock prices updated...
 

Flexion Therapeutics, Inc. stock price

Flexion Therapeutics, Inc. latest news:


  • 10/10/2017 14:08:02

    BRIEF-Flexion Therapeutics- Proposed public offering of 4 mln common shares

    Flexion Therapeutics Inc(FLXN). * Flexion Therapeutics(FLXN) announces proposed public offering of common stock. * Says offering 4.00 million common shares. * Flexion Therapeutics Inc (FLXN) - Flexion intends to use net proceeds from offering to fund manufacturing and commercialization of Zilretta​ Source text for Eikon: Further company coverage:

  • 10/06/2017 13:23:08

    Flexion shares surge 18% on news of FDA approval for non-opioid knee pain injection

    Flexion Therapeutics Inc. shares surged 18% in afternoon trade Friday on news that the company's non-opioid injection for osteoarthritis knee pain has been approved by the Food and Drug Administration. The injection, Zilretta, provides pain relief for 12 weeks. The company expects it will be available in the U.S. by the end of the month, with a full commercial launch in mid-November, at a price of $570 a dose (the figure refers to the injection's wholesale acquisition cost, which is the price a drugmaker offers middleman wholesalers). Osteoarthritis, the most common form of arthritis, is a painful joint disease. Zilretta uses microscopic spherical particles to deliver a combination of a common, short-acting corticosteroid with a poly lactic-co-glycolic acid, the company said. Though there is an urgent need for new non-opioid pain medications, startlingly little progress has been made, MarketWatch reported this summer. Zilretta "may avoid the disruptive blood glucose spikes that can be seen with corticosteroid use in patients coping with both knee OA and type 2 diabetes," said Dr. Steven Russell, assistant professor of medicine at Massachusetts General Hospital Diabetes Research Center. Flexion shares have surged 40% over the last three months, compared with a nearly 6% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/06/2017 13:07:10

    Flexion's knee pain drug gets FDA nod

    Oct 6 (Reuters) - Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

  • 09/14/2017 14:48:30

    BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

    * Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

  • More trends:

    FlexShares Credit-Scored US Corporate Bond Index FSKOR | FlexShares Disciplined Duration MBS Index FundMBSD | Flexsteel Industries, Inc.FLXS | Flextronics International Ltd.FLEX | FLIR Systems, Inc.FLIR | Fluidigm CorporationFLDM | Flushing Financial CorporationFFIC | Foamix Pharmaceuticals Ltd.FOMX | Fogo de Chao, Inc.FOGO | Fonar CorporationFONR |